Summary of results from Cost Utility Analysis (CUA)
| Scenario | Incremental costs | Incremental effects | ICER (5th, 95th centile) |
|---|---|---|---|
| Overall (base case)† | £7090 | 0.139 | £202 571 |
| Rash subgroup | |||
| Base case‡ | £7891 | 0.139 | £56 770 (£29 438 –£89 550 ) |
| Excluding erlotinib costs | £347 | 0.139 | £2496 (£1120–£3895) |
| Including ENR 1st cycle drug costs§ | £9578 | 0.139 | £68 906 (£44 165–£93 276 ) |
†Erlotinib versus placebo (n=647).
‡ER versus placebo (n=456).
§ER (including ENR first cycle erlotinib costs) versus placebo.
ENR, Erlotinib non-rash; ICER, incremental cost-effectiveness ratio.